Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

2(33.3%)

Early Phase 1

1(16.7%)

6Total

Phase 3(3)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02194842Phase 3Active Not Recruiting

Phase III Radium 223 mCRPC-PEACE III

Role: collaborator

NCT03031821Phase 3Terminated

Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome

Role: lead

NCT03266900Early Phase 1Terminated

A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival

Role: collaborator

NCT01305330Completed

The Natural History of Small Renal Masses

Role: collaborator

NCT01099423Phase 3Unknown

Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer

Role: collaborator

NCT01395225Completed

Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer

Role: collaborator

NCT00268710Phase 2Completed

Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

Role: collaborator

NCT00371553Phase 2Completed

Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer

Role: collaborator

All 8 trials loaded